Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
3.810
-0.110 (-2.81%)
Jul 13, 2026, 4:00 PM EDT - Market closed
Opus Genetics Employees
As of December 31, 2025, Opus Genetics had 28 total employees, including 27 full-time and 1 part-time employees. The number of employees increased by 10 or 55.56% compared to the previous year.
Employees
28
Change (1Y)
10
Growth (1Y)
55.56%
Revenue / Employee
$427,964
Profits / Employee
-$3,819,000
Market Cap
314.58M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 28 | 10 | 55.56% | 27 | 1 |
| Dec 31, 2024 | 18 | 4 | 28.57% | 18 | 0 |
| Dec 31, 2023 | 14 | 5 | 55.56% | 14 | 0 |
| Dec 31, 2022 | 9 | 1 | 12.50% | 9 | 0 |
| Dec 31, 2021 | 8 | 3 | 60.00% | 8 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Lyell Immunopharma | 161 |
| Zentalis Pharmaceuticals | 106 |
| Foghorn Therapeutics | 106 |
| Neumora Therapeutics | 92 |
| OmniAb | 89 |
| Lineage Cell Therapeutics | 77 |
| InflaRx | 65 |
IRD News
- 5 days ago - Opus Genetics sets September timeline for retinal disease trial data - TheFly
- 5 days ago - Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results - GlobeNewsWire
- 7 days ago - Opus Genetics FDA alignment further de-risks path to market, says Chardan - TheFly
- 8 days ago - Opus Genetics announces FDA alignment on OPGx-LCA5 trial - TheFly
- 8 days ago - Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease - GlobeNewsWire
- 18 days ago - Opus Genetics to join Russell 3000, Russell 2000 and Russell Microcap Indexes - TheFly
- 18 days ago - Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes - GlobeNewsWire
- 21 days ago - Opus Genetics initiated with an Outperform at RBC Capital - TheFly